{"id":56383,"date":"2026-02-05T20:04:02","date_gmt":"2026-02-05T12:04:02","guid":{"rendered":"https:\/\/flcube.com\/?p=56383"},"modified":"2026-02-05T20:04:03","modified_gmt":"2026-02-05T12:04:03","slug":"lishan-biopharma-licenses-evogenes-ls-lbp-002-for-global-oncology-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56383","title":{"rendered":"Lishan Biopharma Licenses Evogene\u2019s LS-LBP-002 for Global Oncology Development"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Shanghai Lishan Biopharmaceuticals Co., Ltd.<\/strong> announced a licensing agreement with <strong>Israel\u2011based Evogene Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/EVGN:NASDAQ\">NASDAQ:\u202fEVGN<\/a>) for <strong>LS\u2011LBP\u2011002<\/strong>, a live biotherapeutic product designed to enhance immunotherapy response in cancer patients. Lishan assumes global development, manufacturing, and commercialization rights, with Evogene receiving milestone payments and tiered royalties.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-structure-amp-strategic-terms\">Deal Structure &amp; Strategic Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensor<\/strong><\/td><td>Evogene Ltd. (Nasdaq:\u202fEVGN)<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>Shanghai Lishan Biopharmaceuticals Co., Ltd.<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>LS\u2011LBP\u2011002 (formerly BMC128)<\/td><\/tr><tr><td><strong>Technology<\/strong><\/td><td>Live biotherapeutic product (4 strains of human gut bacteria)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Enhances immunotherapy response, stimulates anti\u2011tumor immune activity<\/td><\/tr><tr><td><strong>Rights<\/strong><\/td><td>Global clinical development, manufacturing, and commercialization (Lishan)<\/td><\/tr><tr><td><strong>Financial Terms<\/strong><\/td><td>Milestone payments + tiered royalties<\/td><\/tr><tr><td><strong>Clinical Stage<\/strong><\/td><td>Phase I nearing completion (RCC and NSCLC)<\/td><\/tr><tr><td><strong>Next Steps<\/strong><\/td><td>Phase II initiation; China and US registration applications<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-clinical-progress\">Drug Profile &amp; Clinical Progress<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Composed of four well\u2011defined human gut bacterial strains that enhance responses to immunotherapy and stimulate anti\u2011tumor immune activity<\/li>\n\n\n\n<li><strong>Clinical Data:<\/strong> Phase I trial in renal cell carcinoma (RCC) and non\u2011small cell lung cancer (NSCLC) demonstrated <strong>excellent safety and tolerability<\/strong> with <strong>early signs of efficacy<\/strong><\/li>\n\n\n\n<li><strong>Strategic Advantage:<\/strong> Addresses growing need for immunotherapy combination strategies in solid tumors<\/li>\n\n\n\n<li><strong>Market Position:<\/strong> First live biotherapeutic product targeting cancer immunotherapy enhancement to advance to Phase II<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-commercial-outlook\">Market Impact &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Immunotherapy Enhancement Market:<\/strong> Global market for cancer immunotherapy adjuncts projected to reach <strong>$5\u202fbillion<\/strong> : by 2030<\/li>\n\n\n\n<li><strong>Live Biotherapeutics:<\/strong> Emerging field with limited competition; LS\u2011LBP\u2011002\u2019s early data provides first\u2011mover advantage<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Analysts estimate peak sales potential of <strong>$300\u2013500\u202fmillion<\/strong> : globally if approved, based on combination therapy pricing<\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> Lishan gains differentiated oncology asset; Evogene monetizes its microbiome platform while retaining royalty upside<\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> Phase II trials to initiate <strong>Q2\u202f2026<\/strong>; concurrent US IND and China NDA filings planned for <strong>H2\u202f2026<\/strong><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, regulatory pathways, and revenue projections for LS\u2011LBP\u2011002. Actual results may differ due to clinical trial outcomes, competitive dynamics, and regulatory review processes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Lishan Biopharmaceuticals Co., Ltd. announced a licensing agreement with Israel\u2011based Evogene Ltd. (NASDAQ:\u202fEVGN) for&#8230;<\/p>\n","protected":false},"author":1,"featured_media":56387,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[16,4594,4593,4595],"class_list":["post-56383","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cancer","tag-evogene","tag-lishan-biopharmaceuticals","tag-nasdaq-evgn"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Lishan Biopharma Licenses Evogene\u2019s LS-LBP-002 for Global Oncology Development - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Lishan Biopharmaceuticals Co., Ltd. announced a licensing agreement with Israel\u2011based Evogene Ltd. (NASDAQ:\u202fEVGN) for LS\u2011LBP\u2011002, a live biotherapeutic product designed to enhance immunotherapy response in cancer patients. Lishan assumes global development, manufacturing, and commercialization rights, with Evogene receiving milestone payments and tiered royalties.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56383\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lishan Biopharma Licenses Evogene\u2019s LS-LBP-002 for Global Oncology Development\" \/>\n<meta property=\"og:description\" content=\"Shanghai Lishan Biopharmaceuticals Co., Ltd. announced a licensing agreement with Israel\u2011based Evogene Ltd. (NASDAQ:\u202fEVGN) for LS\u2011LBP\u2011002, a live biotherapeutic product designed to enhance immunotherapy response in cancer patients. Lishan assumes global development, manufacturing, and commercialization rights, with Evogene receiving milestone payments and tiered royalties.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56383\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-05T12:04:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-05T12:04:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0501.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56383#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56383\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Lishan Biopharma Licenses Evogene\u2019s LS-LBP-002 for Global Oncology Development\",\"datePublished\":\"2026-02-05T12:04:02+00:00\",\"dateModified\":\"2026-02-05T12:04:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56383\"},\"wordCount\":337,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56383#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0501.webp\",\"keywords\":[\"Cancer\",\"Evogene\",\"Lishan Biopharmaceuticals\",\"NASDAQ:\u202fEVGN\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56383#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56383\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56383\",\"name\":\"Lishan Biopharma Licenses Evogene\u2019s LS-LBP-002 for Global Oncology Development - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56383#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56383#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0501.webp\",\"datePublished\":\"2026-02-05T12:04:02+00:00\",\"dateModified\":\"2026-02-05T12:04:03+00:00\",\"description\":\"Shanghai Lishan Biopharmaceuticals Co., Ltd. announced a licensing agreement with Israel\u2011based Evogene Ltd. (NASDAQ:\u202fEVGN) for LS\u2011LBP\u2011002, a live biotherapeutic product designed to enhance immunotherapy response in cancer patients. Lishan assumes global development, manufacturing, and commercialization rights, with Evogene receiving milestone payments and tiered royalties.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56383#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56383\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56383#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0501.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0501.webp\",\"width\":1080,\"height\":608,\"caption\":\"Lishan Biopharma Licenses Evogene\u2019s LS-LBP-002 for Global Oncology Development\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56383#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lishan Biopharma Licenses Evogene\u2019s LS-LBP-002 for Global Oncology Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lishan Biopharma Licenses Evogene\u2019s LS-LBP-002 for Global Oncology Development - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Lishan Biopharmaceuticals Co., Ltd. announced a licensing agreement with Israel\u2011based Evogene Ltd. (NASDAQ:\u202fEVGN) for LS\u2011LBP\u2011002, a live biotherapeutic product designed to enhance immunotherapy response in cancer patients. Lishan assumes global development, manufacturing, and commercialization rights, with Evogene receiving milestone payments and tiered royalties.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56383","og_locale":"en_US","og_type":"article","og_title":"Lishan Biopharma Licenses Evogene\u2019s LS-LBP-002 for Global Oncology Development","og_description":"Shanghai Lishan Biopharmaceuticals Co., Ltd. announced a licensing agreement with Israel\u2011based Evogene Ltd. (NASDAQ:\u202fEVGN) for LS\u2011LBP\u2011002, a live biotherapeutic product designed to enhance immunotherapy response in cancer patients. Lishan assumes global development, manufacturing, and commercialization rights, with Evogene receiving milestone payments and tiered royalties.","og_url":"https:\/\/flcube.com\/?p=56383","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-05T12:04:02+00:00","article_modified_time":"2026-02-05T12:04:03+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0501.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56383#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56383"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Lishan Biopharma Licenses Evogene\u2019s LS-LBP-002 for Global Oncology Development","datePublished":"2026-02-05T12:04:02+00:00","dateModified":"2026-02-05T12:04:03+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56383"},"wordCount":337,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=56383#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0501.webp","keywords":["Cancer","Evogene","Lishan Biopharmaceuticals","NASDAQ:\u202fEVGN"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56383#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56383","url":"https:\/\/flcube.com\/?p=56383","name":"Lishan Biopharma Licenses Evogene\u2019s LS-LBP-002 for Global Oncology Development - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=56383#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=56383#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0501.webp","datePublished":"2026-02-05T12:04:02+00:00","dateModified":"2026-02-05T12:04:03+00:00","description":"Shanghai Lishan Biopharmaceuticals Co., Ltd. announced a licensing agreement with Israel\u2011based Evogene Ltd. (NASDAQ:\u202fEVGN) for LS\u2011LBP\u2011002, a live biotherapeutic product designed to enhance immunotherapy response in cancer patients. Lishan assumes global development, manufacturing, and commercialization rights, with Evogene receiving milestone payments and tiered royalties.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56383#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56383"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=56383#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0501.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0501.webp","width":1080,"height":608,"caption":"Lishan Biopharma Licenses Evogene\u2019s LS-LBP-002 for Global Oncology Development"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56383#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Lishan Biopharma Licenses Evogene\u2019s LS-LBP-002 for Global Oncology Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0501.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56383","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56383"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56383\/revisions"}],"predecessor-version":[{"id":56388,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56383\/revisions\/56388"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/56387"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56383"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56383"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56383"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}